Treatment Advances

November 08, 2024

Explore an innovative trial using Azer-cel, an allogeneic CAR T-cell therapy, for relapsed DLBCL patients, focusing on safety and effectiveness.

October 15, 2024

After three years since its original Phase III trial, lisocabtagene maraleucel (liso-cel) is still proving effective for relapsed/refractory DLBCL patients.

September 16, 2024

Learn about the challenges of treating DLBCL with central nervous system involvement, explore available treatment options, and discover the latest research.

August 29, 2024

CAR-T therapy side effects in DLBCL patients are rare after two weeks, but how long should patients be monitored?

July 22, 2024

Is age just a number? Dr. Julio Chavez shares multicenter findings on how CAR T therapy can be effective in those 80 and older.

July 17, 2024

Discover insights from Dr. Ryan Jacobs on AZD0486, a new bispecific antibody for relapsed or refractory lymphoma patients.

June 18, 2024

Dr. David Miklos joins HealthTree Foundation to discuss CAR T-cell advances and what they mean for DLBCL patients.

May 31, 2024

Learn about Loncastuximab Tesirine (Zynlonta), an FDA-approved conjugated antibody for patients with relapsed or refractory DLBCL.

May 09, 2024

Researchers studied whether certain factors influence the need for blood transfusions in DLBCL patients receiving CAR T-cell therapy.

May 02, 2024

Explore Bispecific Antibodies, a promising new treatment option for relapsed/refractory DLBCL. Learn how they work, side effects, and approved therapies.